BDBM50632959 CHEMBL5417464
SMILES Cc1cc(no1)[C@H]1CN(CCN1c1cccc(F)c1)c1cc(F)c2c(N)nncc2c1
InChI Key InChIKey=HXAFDSAENALNGM-UHFFFAOYSA-N
Data 7 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 7 hits for monomerid = 50632959
Affinity DataIC50: 36nMAssay Description:Inhibition of human recombinant N-terminal IgG tagged and C-terminal His tagged C1S (358 to 688 aa residues) expressed in HEK293 cells using Z-Lys-SB...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant N-terminal IgG tagged and C-terminal His tagged C1R (375 to 705 aa residues) expressed in HEK293 cells using Z-Gly-Ar...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant N-terminal IgG tagged and C-terminal His tagged MASP2 (298 to 686 aa residues) expressed in Expi293 cells using Z-Gly...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant N-terminal IgG tagged and C-terminal His tagged factor D (26 to 253 aa residues) expressed in Expi293 cells using Z-L...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human thrombin using L5-FAM/QXLTM 520 thrombin as substrate pretreated with compound followed by substrate addition incubated for 60 mi...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha/beta(Mouse)
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant trypsin using Boc-phe-Ser-Arg-MCA as substrate pretreated with compound followed by substrate addition incubated for ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human recombinant plasmin using Boc-Val-Leu-Lys-MCA as substrate pretreated with compound followed by substrate addition incubated for ...More data for this Ligand-Target Pair
